Gal­der­ma drug pass­es PhI­II in rare skin dis­ease, set­ting the stage for ap­proval re­quest

Der­ma­tol­ogy be­he­moth Gal­der­ma is one step clos­er to reg­u­la­tors’ doorsteps for a mon­o­clon­al an­ti­body it li­censed from Chugai Phar­ma­ceu­ti­cal af­ter a Phase III read­out Wednes­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER